臺北新聞熱綫

Hong Kong - 2025年11月3日 - SeaPRwire，領先的新聞傳播平臺，推出了一款創新的虛擬新聞編輯助手，該系統由SeaPRwire與合作夥伴Asia Presswire (https:/asiapresswire.com)共同開發。該人工智能驅動的系統旨在輔助新聞編輯進行內容編輯和校對，提高編輯工作流程的效率和準確性。 隨著對高質量、無錯誤內容的需求不斷增長，新聞機構和媒體開始越來越依賴技術來簡化其編輯流程。傳統的編輯和校對方法往往耗時且容易出現人為錯誤，尤其是在新聞內容量日益增加的情況下。SeaPRwire的虛擬新聞編輯助手通過提供一個自動化解決方案，利用人工智慧幫助編輯快速而準確地優化新聞內容，從而解決了這一挑戰。 "我們推出的虛擬新聞編輯助手對於希望提高編輯速度和精准度的新聞機構來說，是一次具有革命性的變革，"SeaPRwire客戶支持總監Lucy Clark表示。"通過使用人工智慧技術，系統可以高效地審查內容，糾正語法和句法錯誤，並提供增強新聞文章清晰度和流暢性的建議。它為新聞編輯提供了一個強大的工具，確保內容不僅準確，而且精緻和專業。" 該系統通過分析新聞文章的結構和語言，識別潛在問題，例如拼寫和語法錯誤、語氣不一致或表達不自然。然後，它提供修正和改進的建議，允許編輯快速進行更改，而不妥協工作品質。這在節奏緊張、內容量大的環境中尤為重要。 "隨著新聞機構在緊迫的截止日期下需生產高質量內容的壓力不斷增加，我們的虛擬新聞編輯助手提供了急需的支持，"Clark補充道。"該人工智能系統不僅幫助編輯捕捉他們可能忽視的錯誤，還提升了內容的可讀性和專業性，這對於維護新聞機構的聲譽至關重要。" 通過推出這一先進的工具，SeaPRwire旨在幫助新聞機構、媒體和公關專業人士提高編輯效率，同時保持高標準的品質和準確性。虛擬新聞編輯助手預計將減少手動校對和編輯的時間，讓新聞編輯能夠更多地專注於內容創作和策略。 虛擬新聞編輯助手的推出是SeaPRwire在為不斷發展的媒體環境提供創新解決方案方面邁出的重要一步。通過自動化耗時的編輯任務，該系統幫助新聞機構在要求速度與品質並重的行業中保持競爭力。 SeaPRwire的這一新系統，借助Asia Presswire先進的人工智慧技術，現已向多個行業和地區的用戶開放，提供了一種智能高效的解決方案，以改善編輯工作流程並製作高質量的新聞內容。 關於Asia Presswire   Asia Presswire (https:/asiapresswire.com) 是一家新聞稿發佈服務公司，為全球公關公司、代理機構、組織和企業提供定制化解決方案。他們專注於提供定制化的新聞稿分發服務，包括通過電子郵件直接發送新聞稿給報紙、雜誌和廣播媒體編輯。其廣泛的網路覆蓋172個國家，連接超過230,000個媒體管道以及360萬個自媒體平臺。Asia Presswire支持超過46種語言，包括英語、中文、法語、德語和日語，確保在多語言區域內實現有效溝通。其服務旨在提升品牌的線上可見性和聲譽，有效地與目標受眾建立聯繫。 關於SeaPRwire   SeaPRwire是亞洲領先的媒體傳播管理平臺，旨在賦能公關和傳播專業人士。其品牌洞察計畫通過將客戶與80,000多名記者、編輯、雜誌和線上媒體平臺連接，簡化了傳播管理，同時還與3億多關鍵意見領袖（KOL）粉絲網路對接。借助AI技術，SeaPRwire幫助用戶識別相關媒體和KOL，個性化推介內容，並衡量傳播效果。SeaPRwire在包括日本、中國、韓國、香港、新加坡、越南、泰國、馬來西亞、印尼和菲律賓等地區運營，有效提升品牌認知並教育受眾。 媒體聯繫 Brand: SeaPRwire Contact: Media team Email: cs@seaprwire.com Website: https://seaprwire.com

Hong Kong – November 03, 2025 – SeaPRwire, a leading Public Relations Communication Platform, has launched an innovative Virtual News Editor Assistant, developed in collaboration with its partner Asia Presswire (https:/asiapresswire.com). This AI-powered system is designed to assist news editors with content editing and proofreading, enhancing both the efficiency and accuracy of editorial workflows. As the demand for high-quality, error-free content grows, news organizations and media outlets are increasingly relying on technology to streamline their editorial processes. Traditional methods of editing and proofreading can be time-consuming and prone to human error, especially with the ever-increasing volume of news content being produced. SeaPRwire’s Virtual News Editor Assistant addresses this challenge by offering an automated solution that leverages artificial intelligence to assist editors in refining news content quickly and accurately. “The launch of our Virtual News Editor Assistant is a game-changer for newsrooms looking to improve both speed and precision in their editorial processes,” said Lucy Clark, Customer Support Director at SeaPRwire. “By using AI technology, the system can efficiently review content, correct grammar and syntax errors, and provide suggestions to enhance the clarity and flow of news articles. It offers news editors a powerful tool to ensure their content is not only accurate but also polished and professional.” The system works by analyzing the structure and language of news articles, identifying potential issues such as spelling and grammatical mistakes, inconsistencies in tone, or awkward phrasing. It then provides suggestions for corrections and improvements, allowing editors to make changes quickly without compromising the quality of their work. This is especially valuable in fast-paced environments where deadlines are tight and the volume of content is high. “With the increasing pressure on newsrooms to produce high-quality content under tight deadlines, our Virtual News Editor Assistant provides much-needed support,” Clark added. “The AI-powered system not only helps editors catch mistakes they may have missed but also enhances the overall readability and professionalism of the content, which is crucial for maintaining the reputation of news organizations.” By offering this cutting-edge tool, SeaPRwire aims to help newsrooms, media outlets, and PR professionals improve their editorial efficiency while maintaining high standards of quality and accuracy. The Virtual News Editor Assistant is expected to reduce the time spent on manual proofreading and editing, allowing news editors to focus more on content creation and strategy. The introduction of the Virtual News Editor Assistant is a significant step in SeaPRwire’s ongoing efforts to provide innovative solutions for the evolving media landscape. By automating time-consuming editorial tasks, this system helps news organizations stay competitive in an industry that demands both speed and quality. SeaPRwire’s new system, powered by Asia Presswire’s advanced AI technology, is now available to users across various industries and regions, offering a smart and efficient solution for improving editorial workflows and producing high-quality news content. About Asia Presswire Asia Presswire (https:/asiapresswire.com) is a press release distribution service that provides tailored solutions for public relations firms, agencies, organizations, and corporations worldwide. They specialize in delivering customized press release distribution, including direct-to-editor email delivery to targeted media editors at newspapers, magazines, and broadcast outlets. Their extensive network spans 172 countries, connecting with over 230,000 media outlets and 3.6 million self-media platforms. Supporting over 46 languages, including English, Chinese, French, German, and Japanese, Asia Presswire ensures effective communication across diverse linguistic regions. Their services are designed to enhance brands’ online visibility and reputation, enabling effective connection with target audiences. About SeaPRwire SeaPRwire is a leading earned media communications management platform in Asia, designed to empower PR and communications professionals. Its Branding-Insight Program streamlines communication management by connecting clients with a network of over 80,000 journalists, editors, magazines, and online media outlets, along with 300 million followers of key opinion leaders (KOLs). Leveraging AI-driven technology, SeaPRwire enables users to identify relevant media and KOLs, personalize pitches, and measure the impact of their communications efforts. Operating across regions including Japan, China, Korea, Hong Kong, Singapore, Vietnam, Thailand, Malaysia, Indonesia, and the Philippines, SeaPRwire enhances brand awareness and educates audiences effectively. Media Contact Brand: SeaPRwire Contact: Media team Email: cs@seaprwire.com Website: https://seaprwire.com

SHENZHEN, Oct 30, 2025 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of CMS on 22 April 2025 for details) together with its subsidiaries, holds co-development rights (except for atopic dermatitis (AD)) and exclusive commercialization rights for the Class 1 innovative drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection (“MG-K10” or the “Product”). The New Drug Application (“NDA”) has been accepted by National Medical Products Administration (“NMPA”) on 30 October 2025. The product is intended for the treatment of adult with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. MG-K10 (generic name: Comekibart Injection) is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 and IL-13. With a longer half-life, the Product enables a four-week dosing frequency (currently marketed anti-IL-4Rα drugs require biweekly dosing), which is expected to improve patient adherence. MG-K10 is expected to become the world’s first long-acting anti-IL-4Rα monoclonal antibody to be launched on the market, and has the potential to become the Best-in-Class (BIC). MG-K10 has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical study in adults with moderate-to-severe AD, meeting the primary research endpoint as designed, and at 52 weeks of treatment with MG-K10, proportion of participants with Investigator Global Assessment (IGA) score of 0 or 1, also with an improvement of ≥2 points from baseline is 76.6%; proportion of participants with ≥75% reduction in Eczema Area and Severity Index (EASI 75) from baseline is 94.3 %; proportion of participants with ≥90% reduction in Eczema Area and Severity Index (EASI 90) from baseline is 79.1 %. Regarding safety, most of the Treatment Emergent Adverse Event (TEAE) were Grade 1-2, with no Adverse Event of Special Interest (AESI) or fatal adverse event occurred. The incidence of common adverse reactions (conjunctivitis, injection site reactions, etc.) of drugs with the same target is relatively low for MG-K10. The Product has the potential for the treatment of other type 2 inflammatory diseases, such as asthma, prurigo nodularis, seasonal allergic rhinitis, chronic obstructive pulmonary disease, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Among them, asthma, prurigo nodularis and seasonal allergic rhinitis have all entered the phase III clinical trial stage in China. If MG-K10 is approved, it will provide a new, effective, and safe systemic treatment option for 14.5 million patients with moderate-to-severe AD[1]. Furthermore, MG-K10 will generate synergy with Dermavon’s ruxolitinib cream (for mild to moderate AD), the oral small molecule TYK2 inhibitor CMS-D001 (for moderate to severe AD), and dermatology-grade skincare products of Heling soothing product series, establishing a comprehensive solution for AD that covers various administration routes (injection, oral, and topical) and addresses multiple needs in “treatment + care”, benefiting a wide range of AD patients. Concurrently, it will further enrich Dermavon’s product portfolio in the field of dermatological treatment and reinforce its leading position in skin health sector. On 24 January 2025, CMS through its subsidiaries entered into a Collaboration Agreement (“Agreement”) with Hunan Mabgeek Biotech Co., LTD and its subsidiaries for MG-K10. In accordance with the Agreement and supplementary agreements, CMS has obtained the co-development rights (excluding AD) and exclusive commercialization rights for the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and Singapore; its subsidiary Dermavon has obtained, through its subsidiary, the co-development rights (excluding AD) and exclusive commercialization rights for the Product in the field of dermatological indications in Mainland China. About AD Indication MG-K10’s first indication, AD, is a chronic inflammatory skin disease accompanied by severe itching. It is the most burdensome non-fatal skin disease worldwide and also a chronic disease with a relatively high prevalence and significant disease burden in China. It is estimated that there are over 54 million AD patients in China in 2024. Based on SCORAD scores, the proportion of moderate to severe AD in China was 27%, which means there are over 14.5 million patients[1]. Due to the limitations in efficacy and safety of traditional systemic therapies for AD, moderate to severe AD patients often experience delays in systemic treatment initiation, poor compliance, and suboptimal disease control, leaving a significant unmet need in clinical practice[2]. MG-K10, with its extended dosing interval of once every four weeks, is expected to improve patient adherence and provide a new, effective, and safe systemic treatment option for patients with moderate-to-severe AD. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development  of the Group. Reference: 1. China Insights Consultancy. Industry report on global and China Dermatology Treatment and Care Industry 2. Chinese Society of Dermatology, China Dermatologist Association. Clinical pathway for the diagnosis and treatment of moderate to severe atopic dermatitis in China (2023): an expert consensus[J]. Chinese Journal of Dermatology, 2023, 56(11): 1000-1007. DOI: 10.35541/cjd.20230247. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/